MY207540A - Crystal of pyrimidine compound - Google Patents
Crystal of pyrimidine compoundInfo
- Publication number
- MY207540A MY207540A MYPI2023000055A MYPI2023000055A MY207540A MY 207540 A MY207540 A MY 207540A MY PI2023000055 A MYPI2023000055 A MY PI2023000055A MY PI2023000055 A MYPI2023000055 A MY PI2023000055A MY 207540 A MY207540 A MY 207540A
- Authority
- MY
- Malaysia
- Prior art keywords
- crystal
- compound
- powder
- type
- characteristic peaks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020121520 | 2020-07-15 | ||
| PCT/JP2021/026460 WO2022014638A1 (ja) | 2020-07-15 | 2021-07-14 | ピリミジン化合物の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY207540A true MY207540A (en) | 2025-03-04 |
Family
ID=79554693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2023000055A MY207540A (en) | 2020-07-15 | 2021-07-14 | Crystal of pyrimidine compound |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12492208B2 (https=) |
| EP (1) | EP4183788A4 (https=) |
| JP (1) | JP7391226B2 (https=) |
| KR (1) | KR102914926B1 (https=) |
| CN (1) | CN116249534B (https=) |
| AU (1) | AU2021307245B2 (https=) |
| BR (1) | BR112023000765A2 (https=) |
| MX (1) | MX2023000692A (https=) |
| MY (1) | MY207540A (https=) |
| PH (1) | PH12023550116A1 (https=) |
| TW (1) | TWI905228B (https=) |
| WO (1) | WO2022014638A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024520461A (ja) * | 2021-05-24 | 2024-05-24 | 大鵬薬品工業株式会社 | Ｅｇｆｒ及び／又はｈｅｒ２に異常を有するがんを有する対象の治療方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| CN107207517B (zh) * | 2015-01-30 | 2019-06-07 | 大鹏药品工业株式会社 | 稠合嘧啶化合物的盐及其结晶 |
| JP6537601B2 (ja) * | 2015-05-12 | 2019-07-03 | 大鵬薬品工業株式会社 | アザ二環式化合物の結晶 |
| JP6141568B1 (ja) | 2015-09-01 | 2017-06-07 | 大鵬薬品工業株式会社 | 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩 |
| WO2018159613A1 (ja) | 2017-02-28 | 2018-09-07 | 大鵬薬品工業株式会社 | ピラゾロ［３，４－ｄ］ピリミジン化合物を用いた抗腫瘍効果増強剤 |
| US11856345B2 (en) | 2018-06-28 | 2023-12-26 | Nec Corporation | Remote control apparatus, remote control method, and program |
| WO2020045461A1 (ja) * | 2018-08-29 | 2020-03-05 | 大鵬薬品工業株式会社 | ピラゾロ［３，４－ｄ］ピリミジン化合物を有効成分とする治療剤 |
| CA3121722C (en) | 2019-01-11 | 2024-01-16 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound or salt thereof |
| JP7164455B2 (ja) | 2019-01-31 | 2022-11-01 | 理想科学工業株式会社 | 容器 |
| US20230285397A1 (en) * | 2020-07-15 | 2023-09-14 | Taiho Pharmaceutical Co., Ltd. | Egfr inhibitor |
| EP4183395A4 (en) * | 2020-07-15 | 2024-07-24 | Taiho Pharmaceutical Co., Ltd. | PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT |
-
2021
- 2021-07-14 US US18/015,997 patent/US12492208B2/en active Active
- 2021-07-14 KR KR1020237003585A patent/KR102914926B1/ko active Active
- 2021-07-14 MX MX2023000692A patent/MX2023000692A/es unknown
- 2021-07-14 TW TW110125852A patent/TWI905228B/zh active
- 2021-07-14 MY MYPI2023000055A patent/MY207540A/en unknown
- 2021-07-14 AU AU2021307245A patent/AU2021307245B2/en active Active
- 2021-07-14 CN CN202180061122.XA patent/CN116249534B/zh active Active
- 2021-07-14 WO PCT/JP2021/026460 patent/WO2022014638A1/ja not_active Ceased
- 2021-07-14 BR BR112023000765A patent/BR112023000765A2/pt unknown
- 2021-07-14 PH PH1/2023/550116A patent/PH12023550116A1/en unknown
- 2021-07-14 EP EP21842747.4A patent/EP4183788A4/en not_active Withdrawn
- 2021-07-14 JP JP2022536418A patent/JP7391226B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PH12023550116A1 (en) | 2024-06-24 |
| CA3189457A1 (en) | 2022-01-20 |
| AU2021307245B2 (en) | 2024-02-29 |
| KR20230034341A (ko) | 2023-03-09 |
| CN116249534B (zh) | 2025-03-25 |
| TWI905228B (zh) | 2025-11-21 |
| TW202216717A (zh) | 2022-05-01 |
| CN116249534A (zh) | 2023-06-09 |
| US12492208B2 (en) | 2025-12-09 |
| KR102914926B1 (ko) | 2026-01-19 |
| EP4183788A4 (en) | 2024-07-17 |
| BR112023000765A2 (pt) | 2023-02-07 |
| JPWO2022014638A1 (https=) | 2022-01-20 |
| AU2021307245A1 (en) | 2023-03-02 |
| US20230331730A1 (en) | 2023-10-19 |
| EP4183788A1 (en) | 2023-05-24 |
| WO2022014638A1 (ja) | 2022-01-20 |
| JP7391226B2 (ja) | 2023-12-04 |
| MX2023000692A (es) | 2023-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020157652A8 (en) | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 | |
| CA2397450A1 (en) | Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| IL275762B2 (en) | History of PHENYL-SO2-NH-C(=O)-PHENYL-PIPERAZINE-CH2-1,2-CYCLOHEXANE-BICYCLO[1.1.1]PENTANE and spirit preparations containing them | |
| EP4467549A3 (en) | Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives | |
| GEP20227434B (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| SE0202463D0 (sv) | Novel compounds | |
| NZ590334A (en) | ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF | |
| MY207540A (en) | Crystal of pyrimidine compound | |
| GEP20247655B (en) | Crystalline salt forms of kinase inhibitor | |
| MX2021011286A (es) | Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia. | |
| NZ602710A (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| EA201892566A1 (ru) | Кристаллический полиморф 15в-гидрокси-осатерона ацетата | |
| JOP20200327A1 (ar) | مركبات سيانوتريازول واستخداماتها | |
| NZ601635A (en) | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent | |
| MX2010005787A (es) | Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina. | |
| WO2020016302A8 (en) | A xinafoate salt of a jak inhibiting compound | |
| CR20230479A (es) | Formas de sales y sólidas de un inhibidor de cinasas | |
| MX2025001201A (es) | Sales y cristales novedosos | |
| MY200551A (en) | The salts of a compound and the crystalline forms thereof | |
| MY202100A (en) | Crystal | |
| RU2014134050A (ru) | Тетрагидрофолаты в комбинации с ингибиторами egfr | |
| PH12020551736A1 (en) | The crystalline forms of a compound | |
| EP4327814A3 (en) | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| MX2022004274A (es) | Las sales de un compuesto y sus formas cristalinas. |